Browsing Tag
Cipla Limited
7 posts
Why Cipla’s Goa facility VAI status matters more than a routine USFDA inspection update
Cipla has regulatory breathing room, but launches still matter. The Goa VAI status may decide how investors price its US growth story. Read more.
Who is really leading Indian pharma in 2026? The top 10 companies explained beyond the hype
Discover the top 10 pharma companies in India in 2026, who leads by revenue, reach, and strategy, and why the ranking is more complex than it looks.
Cipla and Orbicular bring first generic liraglutide for obesity to U.S. market, targeting $127m opportunity
Cipla launches generic Saxenda (liraglutide) in the U.S. via partner Orbicular's FDA approval. What this means for GLP-1 generics competition, payers, and Cipla's peptide strategy. Read more.
Pfizer signs five-year marketing deal with Cipla for Corex, Dolonex, and Neksium in India
Pfizer Limited has partnered with Cipla Limited to market and distribute four major brands in India. Find out what this means for both companies and the industry.
Cipla boosts investment in Ethris to advance mRNA therapies in emerging markets
Cipla Limited has announced an additional investment of EUR 3 million in Ethris GmbH, further strengthening its involvement…
Sanofi India partners with Cipla Limited for enhanced distribution of CNS product range
In a strategic move poised to reshape the landscape of Central Nervous System (CNS) medication accessibility in India,…
Cipla Limited’s subsidiary InvaGen Pharmaceuticals recalls Vigabatrin Oral Solution
In an important safety announcement, Cipla Limited revealed that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., based in the…